{
  "first_published_at": "2008-04-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085185", 
  "title": "Antidepressants: suicidal thoughts and behaviour - summary report", 
  "tags": "{\"parsed_therapeutic\": [\"psychiatry\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Psychiatry\"]}", 
  "_document_number": 291, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Antidepressants: suicidal thoughts and behaviour - summary report</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: April 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Data for the risk of suicidal thoughts and behaviour with antidepressants have been assessed both within Europe and by the US Food and Drug Administration. The benefits of selective serotonin reuptake inhibitor antidepressant medicines continue to outweigh the risks in their licensed indications.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p align=\"left\">A report by the European Pharmacovigilance Working Party on <a href=\"http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/PhVWP_Recommendations/Antidepressants/PAR_suicidal_thoughts.pdf\" target=\"_blank\">the risk of suicidal thoughts and behaviour with antidepressants</a> has recently been published. The report summarises the data for this risk that have been assessed both within Europe and by the US Food and Drug Administration. The benefits of selective serotonin reuptake inhibitor antidepressant medicines continue to outweigh the risks in their licensed indications.</p><p align=\"left\">&nbsp;</p><p align=\"left\"><em>Article citation: Drug Safety Update April 2008; Vol 1, Issue 9: 10</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p align=\"left\">A report by the European Pharmacovigilance Working Party on <a href=\"http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/PhVWP_Recommendations/Antidepressants/PAR_suicidal_thoughts.pdf\" target=\"_blank\">the risk of suicidal thoughts and behaviour with antidepressants</a> has recently been published. The report summarises the data for this risk that have been assessed both within Europe and by the US Food and Drug Administration. The benefits of selective serotonin reuptake inhibitor antidepressant medicines continue to outweigh the risks in their licensed indications.</p><p align=\"left\">&#160;</p><p align=\"left\"><em>Article citation: Drug Safety Update April 2008; Vol 1, Issue 9: 10</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-04-01", 
  "date_last_modified": "2010-08-19", 
  "_assets": [], 
  "_item_id": 291, 
  "summary": "", 
  "body": "Article date: April 2008\n\nA report by the European Pharmacovigilance Working Party on [the risk of suicidal thoughts and behaviour with antidepressants](http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/PhVWP_Recommendations/Antidepressants/PAR_suicidal_thoughts.pdf) has recently been published. The report summarises the data for this risk that have been assessed both within Europe and by the US Food and Drug Administration. The benefits of selective serotonin reuptake inhibitor antidepressant medicines continue to outweigh the risks in their licensed indications.\n\nÂ \n\nArticle citation: Drug Safety Update April 2008; Vol 1, Issue 9: 10\n"
}